

Seirbhís Aisíoca Príomhchúraim
Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 XKF3
Guthán: 01 8647100



Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3
Tel: 01- 8647100

David Cullinane, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

1st March, 2021

PQ: 8410/21

To ask the Minister for Health the drugs which were considered at the January HSE drugs group meeting; the stage at which each are at in their application; the actions emerging from the meeting in tabular form; and if he will make a statement on the matter. -David Cullinane.

Dear Deputy Cullinane,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 8410/21), which you submitted to the Minister for Health for response.

The minutes from the Drugs Group meeting in January 2021 have now been published online.

<https://www.hse.ie/eng/about/who/cpu/drugs-group-minutes/hse-drugs-group-minutes-january-2021.pdf>

The minutes detail the medicines that were included on the January 2021 meeting agenda.

The Drugs Group recommendation for each application that was reviewed, in the time that was available, is also included in the published minutes.

All recommendations were subsequently progressed by the Drugs Group Secretariat (held by the Corporate Pharmaceutical unit) to the HSE Executive Management Team for a decision. The EMT supported the recommendations and as a result these decisions are currently being progressed by the HSE.

Where the HSE EMT has considered a recommendation of the Drugs Group, and when circumstances arise where it is minded to accept a Drugs Group recommendation of non-reimbursement, the HSE is required (in line with the Health [Pricing and Supply of Medical Goods] Act 2013) to set out in detail a notice of any proposed decision to an applicant company. The HSE where such circumstances apply, is also required to provide at least a 28 day period (from the formal written notice of proposal) to enable an applicant company to consider any such proposal not to reimburse and to make representations to the HSE where it is so minded. The HSE is required to consider any such representations in advance of a formal decision.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Suzanne Doyle'.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service

